Streetbeat News

IVBIY

Innovent Biologics Inc

http://innoventbio.com

CEO

De-Chao Yu

Industry

Research and Development in Biotechnology

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Innovent Biologics' psoriasis drug, Picankibart, has shown positive results in a Phase 3 study, leading to the acceptance of its New Drug Application in China. The drug demonstrated significant efficacy and safety, offering potential benefits for patients with moderate to severe plaque psoriasis.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:49 am

Innovent presented Phase 1 clinical data of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein, combined with bevacizumab for advanced colorectal cancer. The study showed promising anti-tumor efficacy and good safety profile.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:05 am

Innovent's Phase 3 DREAMS-2 trial shows mazdutide's superiority over dulaglutide in glycemic control and weight reduction for Chinese Type 2 Diabetes patients. Mazdutide also improved cardiometabolic risk factors.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 7:55 am

Innovent Biologics presented updated results on Dupert (fulzerasib) for KRAS G12C-mutated NSCLC at the 2024 World Conference on Lung Cancer. The drug, a KRAS G12C inhibitor, was approved by the NMPA in August 2024 for advanced NSCLC patients.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 7:56 am

Innovent Biologics has received FDA Fast Track Designation for its bispecific antibody, IBI363, as a monotherapy for advanced melanoma. This designation could expedite the development and review process, potentially bringing the treatment to market faster.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 7:08 am

HUTCHMED and Innovent have announced that their New Drug Application (NDA) for the combination of fruquintinib and sintilimab for treating advanced endometrial cancer has been accepted in China with Priority Review status. This follows the Breakthrough Therapy designation received in July 2023. This marks the first regulatory filing for fruquintinib in combination with an immune checkpoint inhibitor.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 5:43 am

Innovent Biologics, Inc. (IVBIY) and AnHeart Therapeutics announced the acceptance of a second New Drug Application (NDA) by China's NMPA for taletrectinib, a treatment for ROS1-positive lung cancer. This marks a significant step in providing a new first-line treatment option for patients with this type of cancer.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 6:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.